Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Last trade$3.71
Day change-$0.12 (-3.13%)
Day range$3.64 – $3.88
Volume50,040
Market cap$7M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for ADXN.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for ADXN.
Recent news
Company coverage with links to the original publishers.
Neurosterix, a spin-out company from Addex Therapeutics, has successfully closed a $105 million Series B financing round led by leading life science investors. The funding will primarily support Phase 2 clinical development of NTX-253, a selective muscarinic M4 positive allosteric modulator for schizophrenia treatment. Addex retains an 8.5% equity stake valued at $18.6 million and did not participate in the financing.
Addex Therapeutics announced the issuance of 93 million new registered shares at CHF 0.01 nominal value, fully subscribed by its wholly-owned subsidiary Addex Pharma S.A. The move increases issued share capital to CHF 3,116,544.96 while maintaining unchanged outstanding shares, designed to provide additional future financing flexibility for the clinical-stage biopharmaceutical company.
Addex Therapeutics invested CHF 2 million in Stalicla, a clinical-stage company focusing on precision medicine for neurodevelopmental disorders. The investment supports Stalicla's autism drug candidates and clinical trials, with Addex CEO Tim Dyer joining Stalicla's Board of Directors.
Stalicla, a Swiss clinical-stage biotech company, secured CHF 2 million in financing from Addex Therapeutics to advance its precision medicine neurodevelopmental disorder programs, including preparing for Series C financing and progressing clinical trials for autism and substance use disorder treatments.
Addex Therapeutics reported a strong cash position of CHF2.8 million at the end of Q1 2025. The company's GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models, and it regained rights to its phase 2 mGlu2 PAM asset.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.